Corrigendum: Cost-effectiveness of avelumab maintenance therapy plus best supportive care vs. best supportive care alone for advanced or metastatic urothelial carcinoma
oleh: Qian Xie, Hanrui Zheng, Ye Chen, Xingchen Peng
| Format: | Article |
|---|---|
| Diterbitkan: | Frontiers Media S.A. 2022-07-01 |
Deskripsi
Subjek
programmed cell death ligand 1; avelumab; cost-effective; advanced or metastatic urothelial cancer; maintenance therapy